Oral, Elif A.
Gorden, Phillip
Cochran, Elaine
Araújo-Vilar, David
Savage, David B.
Long, Alison
Fine, Gregory
Salinardi, Taylor
Brown, Rebecca J.
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases
UM Lipodystrophy Fund
White Point Foundation of Turkey
Wellcome Trust (WT 107064)
MRC Metabolic Disease Unit (MRC_MC_UU_12012.1)
The National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre
NIHR Rare Disease Translational Research Collaboration
Article History
Received: 23 October 2018
Accepted: 5 February 2019
First Online: 25 February 2019
Compliance with ethical standards
:
: E.A.O. has served as a consultant to Aegerion Pharmaceuticals, Akcea Therapeutics, AstraZeneca, Regeneron Therapeutics, and Thera Therapeutics; has received grant support from Aegerion Pharmaceuticals, Akcea Therapeutics, AstraZeneca, Gemphire Therapeutics, GIDynamics, and Ionis Pharmaceuticals; and has received nonmaterial support from Aegerion Pharmaceuticals and Boehringer Ingelheim. D.A.V. and D.B.S. have served as consultants to Aegerion Pharmaceuticals. A.L. and T.S. are former employees and G.F. is a current employee of Aegerion Pharmaceuticals. E.C., P.G., and R.B. report no conflicts of interest.
: The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice and was approved by the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Arthritis and Musculoskeletal and Skin Diseases institutional review boards.
: Informed consent was obtained from all patients or their legal guardians.